Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2002

View Archived Issues

Baxter submits BLA for rAHF-PFM

Atrix files IND for transmucosal sumatriptan

Nolvadex warnings strengthened

Immune Network presents overview of drug candidate development

Fujisawa seeks Canadian approval for micafungin

Hepatitis B pharmaccine enters phase II

PS-1145 reduces multiple myeloma growth and survival through inhibition of NF-kB activation

Selective glucocorticoid receptor antagonist demonstrates clinical antidepressant activity

Traditional medicinal products with potential in Alzheimer's disease

New IL-4 variant evaluated for safety in phase I trial in MS patients

Favorable NMB characteristics determined for TAAC3 in animals

Pretreatment with Genasense being tested for advanced malignant melanoma

In vitro evidence for efficacy of bosentan in malignant melanoma presented in Paris

Resiquimod prevents recurrence of genital herpes

Selective Lys-gingipain inhibitors for use in periodontitis

Ajinomoto presents novel SGLT2 inhibitors

New PGD2 antagonists for use in upper respiratory tract disorders

Novel analgesic naphthyridines identified at Otsuka

Takeda reports novel CCR5 antagonists and their use in HIV infection

Nociceptin receptor ligands claimed by Nippon Shinyaku

Fampridine-SR enters two phase III trials for chronic spinal cord injury

Inhibitors of NF-kB activation and their use in inflammatory disorders

HuMax-IL-15 effective in mouse model of psoriasis

NeoPharm submits IND for LE-SN-38

CPMP recommends approval of new indication for clopidogrel

Nonapprovable letter issued for Risperdal Consta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...